Key Facts updated Jan 2019
*This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.
OPDIVO®, $6.7 billion
ELIQUIS®, $6.4 billion
ORENCIA®, $2.7 billion
SPRYCEL®, $2.0 billion
YERVOY®, $1.3 billion
BARACLUDE®, $744 million
SUSTIVA® franchise, $283 million
REYATAZ® franchise, $427 million
Hepatitis C franchise, $17 million
Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.
Bristol-Myers Squibb Corporate B-roll
This B-roll includes a collection of footage of Bristol-Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.
Achieving Our Vision Through Leading Scientific Innovation
The new company is united by one vision for the future, and we are already making tangible progress toward achieving it.